NLM logo
1,514 results
  1. ... dose aripiprazole for bipolar disorder. Key Points: Major AEs The effects between different doses of SGAs in terms of major AEs during ... least low SOE for an outcome of general AEs in studies comparing different doses of SGAs. The doses considered are identified for ...
  2. ... cathartic, and is used in obstinate visceral obstructions, Ae. Dose, gr. vj to Z se, gr. x to ^ ... gen- tiana, summit, ehamadr., centaur, min. aa p. ae.) Dose, ^ss to ^j. Pulvis Emmenagogus, P. myrrhae compositus ��� p. ...
  3. ... gen- liana, summit, chamadr., centaur, min. aa p. ae.) Dose, 3 ss to 3j. Pulvis e Gummi Gutta, P. ... tana- ceti, fol. scordii, senna, rhmi. aa. p. ae, fiat pulvis. Ph. P.) Dose, 9 j to 3 j. Pulvis Ipecacuanha Compositus, ...
  4. ... delay increases or to reduce doses due to AEs. The initial dose was 0.3mg/kg/day (rounded to the ...
  5. ... aristoloch., gentianx, summit, chamozdr., centaur, ruin, aa p.ae.) Dose, gss to gj. Pulvis Emmenagogus, P. myrrhae compo- ... absinth., tanaceti, fol. scordii, sennx, rhei. aa p. ae, fiat pulvis. Ph. P.) Dose, ^j to gj. Pulvis Hydragogcs, P. e gummi ...
  6. ... gen- tiana, summit, chamadr., centaur, min. aa p. ae.) Dose, %** to t^j. Pulvis Emmenagogus, P. myrrhae compositus ��� ...
  7. ... R.���Tinct. ferri. muriatis. Tinct. aloes, aa p. ae. Dose, 20 drops, three or four times a day. ...
  8. ... Stokes. R.���Tinct. ferri chloridi. Aloes, aa p. ae. Dose, 20 drops, three or four times a day. ...
  9. ... classes in terms of the incidence of GI AEs for people taking low-dose aspirin. Cardiovascular adverse events Knee osteoarthritis Four RCTs ... non-selective NSAIDs had similar incidences of cardiovascular AEs in adults with osteoarthritis, regardless of ... and hepatic adverse events Knee osteoarthritis ...
  10. ... explore the safety and efficacy of orally administered AE-941/Neovastat when administered in escalating doses (30, 60, 120, and 240 mL/day). No ... II trials g Various advanced, refractory solid tumors AE-941/ Neovastat (shark) ... survival, higher versus lower doses, patients with stage III/IV non-small cell ...
first · previous · 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · next · last